| 1. |
|
|
| 2. |
- Andersson, Johan, 1971-, et al.
(författare)
-
On the universality of the Epstein zeta function
- 2020
-
Ingår i: Commentarii Mathematici Helvetici. - : European Mathematical Society Publishing House. - 0010-2571 .- 1420-8946. ; 95:1, s. 183-209
-
Tidskriftsartikel (refereegranskat)abstract
- We study universality properties of the Epstein zeta function E-n(L,s) for lattices L of large dimension n and suitable regions of complex numbers s. Our main result is that, as n -> infinity, E-n(L,s) is universal in the right half of the critical strip as L varies over all n-dimensional lattices L. The proof uses a novel combination of an approximation result for Dirichlet polynomials, a recent result on the distribution of lengths of lattice vectors in a random lattice of large dimension and a strong uniform estimate for the error term in the generalized circle problem. Using the same approach we also prove that, as n -> infinity, E-n(L-1,s) - E-n(L-2,s) is universal in the full half-plane to the right of the critical line as E-n(L,s) varies over all pairs of n-dimensional lattices. Finally, we prove a more classical universality result for E-n(L,s) in the s-variable valid for almost all lattices L of dimension n. As part of the proof we obtain a strong bound of E-n(L,s) on the critical line that is subconvex for n >= 5 and almost all n-dimensional lattices L.
|
|
| 3. |
- Andersson, Johan, et al.
(författare)
-
On the universality of the Epstein zeta function
- 2020
-
Ingår i: Commentarii Mathematici Helvetici. - 0010-2571 .- 1420-8946. ; 95:1, s. 183-209
-
Tidskriftsartikel (refereegranskat)abstract
- We study universality properties of the Epstein zeta function E-n(L,s) for lattices L of large dimension n and suitable regions of complex numbers s. Our main result is that, as n -> infinity, E-n(L,s) is universal in the right half of the critical strip as L varies over all n-dimensional lattices L. The proof uses a novel combination of an approximation result for Dirichlet polynomials, a recent result on the distribution of lengths of lattice vectors in a random lattice of large dimension and a strong uniform estimate for the error term in the generalized circle problem. Using the same approach we also prove that, as n -> infinity, E-n(L-1,s) - E-n(L-2,s) is universal in the full half-plane to the right of the critical line as E-n(L,s) varies over all pairs of n-dimensional lattices. Finally, we prove a more classical universality result for E-n(L,s) in the s-variable valid for almost all lattices L of dimension n. As part of the proof we obtain a strong bound of E-n(L,s) on the critical line that is subconvex for n >= 5 and almost all n-dimensional lattices L.
|
|
| 4. |
- Balkanova, O., et al.
(författare)
-
NON-VANISHING OF MAASS FORM L-FUNCTIONS AT THE CENTRAL POINT
- 2021
-
Ingår i: Proceedings of the American Mathematical Society. - : American Mathematical Society (AMS). - 0002-9939 .- 1088-6826. ; 149:2, s. 509-523
-
Tidskriftsartikel (refereegranskat)abstract
- In this paper, we consider the family {L-j(s)}(j=1)(infinity) of L-functions associated to an orthonormal basis {u(j)}(j=1)(infinity) of even Hecke-Maass forms for the modular group SL(2, Z) with eigenvalues {lambda(j) = kappa(2)(j) + 1/4}(j=1)(infinity). We prove the following effective non-vanishing result: At least 50% of the central values L-j(1/2) with kappa(j) <= T do not vanish as T -> infinity. Furthermore, we establish effective non-vanishing results in short intervals.
|
|
| 5. |
- Devin, L., et al.
(författare)
-
Low-lying zeros in families of holomorphic cusp forms: the weight aspect
- 2022
-
Ingår i: Quarterly Journal of Mathematics. - : Oxford University Press (OUP). - 0033-5606 .- 1464-3847. ; 73:4, s. 1403-1426
-
Tidskriftsartikel (refereegranskat)abstract
- We study low-lying zeros of L-functions attached to holomorphic cusp forms of level 1 and large even weight. In this family, the Katz-Sarnak heuristic with orthogonal symmetry type was established in the work of Iwaniec, Luo and Sarnak for test functions phi satisfying the condition supp((phi) over cap) subset of (-2, 2). We refine their density result by uncovering lower-order terms that exhibit a sharp transition when the support of (phi) over cap reaches the point 1. In particular, the first of these terms involves the quantity (phi) over cap (1) which appeared in the previous work of Fouvry-Iwaniec and Rudnick in symplectic families. Our approach involves a careful analysis of the Petersson formula and circumvents the assumption of the Generalized Riemann Hypothesis (GRH) for higher-degree automorphic L-functions. Finally, when supp((phi) over cap) subset of (-1, 1) we obtain an unconditional estimate which is significantly more precise than the prediction of the L-functions ratios conjecture.
|
|
| 6. |
- Frodlund, Martina, et al.
(författare)
-
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. : A Swedish nationwide study (COVID19-REUMA)
- 2023
-
Ingår i: Vaccine. - : Elsevier BV. - 0264-410X .- 1873-2518. ; 41:20, s. 3247-3257
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: To elucidate antibody responses after the second and third dose of COVID-19 vaccine in patients with inflammatory rheumatic diseases (IRD) treated with biologic/targeted disease modifying anti-rheumatic drugs (b/ts DMARDs).Methods: Antibody levels to antigens representing spike full length protein and spike S1 were measured before vaccination, 2-12 weeks after the second dose, before and after the third dose using multiplex bead-based serology assay. Positive antibody response was defined as antibody levels over cut off (seropositivity) in seronegative individuals or >= 4-fold increase in antibodies in individuals seropositive for both spike proteins.Results: Patients (n = 414) receiving b/ts DMARDs (283 had arthritis, 75 systemic vasculitis and 56 other autoimmune diseases) and controls (n = 61) from five Swedish regions participated. Treatments groups were: rituximab (n = 145); abatacept (n = 22); Interleukin 6 receptor inhibitors [IL6i (n = 79)]; JAnus Kinase Inhibitors [JAKi (n = 58)], Tumour Necrosis Factor inhibitor [TNFi (n = 68)] and Interleukin12/23/17 inhibitors [IL12/23/17i (n = 42)]. Percentage of patients with positive antibody response after two doses was significantly lower in rituximab (33,8%) and abatacept (40,9%) (p < 0,001) but not in IL12/23/17i, TNFi or JAKi groups compared to controls (80,3%). Higher age, ritux-imab treatment and shorter time between last rituximab course and vaccination predicted impaired anti-body response. Antibody levels collected 21-40 weeks after second dose decreased significantly (IL6i: p = 0,02; other groups: p < 0,001) compared to levels at 2-12 week but most participants remained seropositive. Proportion of patients with positive antibody response increased after third dose but was still significantly lower in rituximab (p < 0,001).Conclusions: Older individuals and patients on maintenance rituximab have an impaired response after two doses of COVID-19 vaccine which improves if the time between last rituximab course and vaccina-tion extends and also after an additional vaccine dose. Rituximab patients should be prioritized for (2023) booster vaccine doses. TNFi, JAKi and IL12/23/17i does not diminished humoral response to primary and an additional vaccination.
|
|
| 7. |
- Frodlund, Martina, et al.
(författare)
-
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs : a Swedish nationwide study (COVID-19-REUMA)
- 2024
-
Ingår i: Microbiology Spectrum. - : AMER SOC MICROBIOLOGY. - 2165-0497. ; 12:4
-
Tidskriftsartikel (refereegranskat)abstract
- Studies investigating the immunogenicity of additional COVID-19 vaccine doses in immunosuppressed patients with inflammatory rheumatic diseases (IRD) are still limited. The objective was to explore the antibody response including response to omicron virus subvariants (sBA.1 and sBS.2) after third and fourth COVID-19 vaccine doses in Swedish IRD patients treated with immunomodulating drugs compared to controls. Antibody levels to spike wild-type antigens (full-length protein and S1) and the omicron variants sBA.1 and sBA.2 (full-length proteins) were measured. A positive response was defined as having antibody levels over cut-off or ≥fourfold increase in post-vaccination levels for both antigens. Patients with arthritis, vasculitis, and other autoimmune diseases (n = 414), and controls (n = 61) receiving biologic/targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) with or without conventional synthetic DMARDs participated. Of these, blood samples were available for 370 patients and 52 controls after three doses, and 65 patients and 15 controls after four doses. Treatment groups after three vaccine doses were rituximab (n = 133), abatacept (n = 22), IL6r inhibitors (n = 71), JAnus Kinase inhibitors (JAK-inhibitors) (n = 56), tumor necrosis factor inhibitor (TNF-inhibitors) (n = 61), IL12/23/17 inhibitors (n = 27), and controls (n = 52). The percentage of responders after three and four vaccine doses was lower in rituximab-treated patients (59% and 57%) compared to controls (100%) (P < 0.001). After three doses, the percentage of responders in all other groups was 100%, including response to omicron sBA.1 and sBA.2. In rituximab-treated patients, higher baseline immunoglobulin G (IgG) and longer time-period between rituximab and vaccination predicted better response. In this Swedish nationwide study including IRD patients three and four COVID-19 vaccine doses were immunogenic in patients treated with IL6r inhibitors, TNF-inhibitors, JAK-inhibitors, and IL12/23/17-inhibitors but not in rituximab. As >50% of rituximab patients responded to vaccines including omicron subvariants, these patients should be prioritized for additional vaccine doses.
|
|
| 8. |
- Frodlund, Martina, et al.
(författare)
-
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)
- 2024
-
Ingår i: MICROBIOLOGY SPECTRUM. - : AMER SOC MICROBIOLOGY. - 2165-0497. ; 12:4
-
Tidskriftsartikel (refereegranskat)abstract
- Studies investigating the immunogenicity of additional COVID-19 vaccine doses in immunosuppressed patients with inflammatory rheumatic diseases (IRD) are still limited. The objective was to explore the antibody response including response to omicron virus subvariants (sBA.1 and sBS.2) after third and fourth COVID-19 vaccine doses in Swedish IRD patients treated with immunomodulating drugs compared to controls. Antibody levels to spike wild-type antigens (full-length protein and S1) and the omicron variants sBA.1 and sBA.2 (full-length proteins) were measured. A positive response was defined as having antibody levels over cut-off or >= fourfold increase in post-vaccination levels for both antigens. Patients with arthritis, vasculitis, and other autoimmune diseases (n = 414), and controls (n = 61) receiving biologic/targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) with or without conventional synthetic DMARDs participated. Of these, blood samples were available for 370 patients and 52 controls after three doses, and 65 patients and 15 controls after four doses. Treatment groups after three vaccine doses were rituximab (n = 133), abatacept (n = 22), IL6r inhibitors (n = 71), JAnus Kinase inhibitors (JAK-inhibitors) (n = 56), tumor necrosis factor inhibitor (TNF-inhibitors) (n = 61), IL12/23/17 inhibitors (n = 27), and controls (n = 52). The percentage of responders after three and four vaccine doses was lower in rituximab-treated patients (59% and 57%) compared to controls (100%) (P < 0.001). After three doses, the percentage of responders in all other groups was 100%, including response to omicron sBA.1 and sBA.2. In rituximab-treated patients, higher baseline immunoglobulin G (IgG) and longer time-period between rituximab and vaccination predicted better response. In this Swedish nationwide study including IRD patients three and four COVID-19 vaccine doses were immunogenic in patients treated with IL6r inhibitors, TNF-inhibitors, JAK-inhibitors, and IL12/23/17-inhibitors but not in rituximab. As >50% of rituximab patients responded to vaccines including omicron subvariants, these patients should be prioritized for additional vaccine doses. IMPORTANCE Results from this study provide further evidence that additional doses of COVID-19 vaccines are immunogenic and result in satisfactory antibody response in a majority of patients with inflammatory rheumatic diseases (IRD) receiving potent immunomodulating treatments such as biological or targeted disease-modifying anti-rheumatic drugs (DMARDs) given as monotherapy or combined with traditional DMARDs. We observed that rituximab treatment, both as monotherapy and combined with csDMARDs, impaired antibody response, and only roughly 50% of patients developed a satisfactory antibody response including response to omicron subvariants after the third vaccine. In addition, higher IgG levels at the last rituximab course before the third vaccine dose and a longer time after the last rituximab treatment increased the chance of a satisfactory antibody response. These results indicate that rituximab-treated patients should be prioritized for additional vaccine doses. CLINICAL TRIALS EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with number 2021-000880-63.
|
|
| 9. |
- Liu, Yen Po, et al.
(författare)
-
Low temperature scanning tunneling microscopy and spectroscopy on laterally grown InxGa1-xAs nanowire devices
- 2020
-
Ingår i: Applied Physics Letters. - : AIP Publishing. - 0003-6951 .- 1077-3118. ; 117:16
-
Tidskriftsartikel (refereegranskat)abstract
- Laterally grown InxGa1-xAs nanowires (NWs) are promising candidates for radio frequency and quantum computing applications, which, however, can require atomic scale surface and interface control. This is challenging to obtain, not least due to ambient air exposure between fabrication steps, which induces surface oxidation. The geometric and electronic surface structures of InxGa1-xAs NWs and contacts, which were grown directly in a planar configuration, exposed to air, and then subsequently cleaned using atomic hydrogen, are studied using low-temperature scanning tunneling microscopy and spectroscopy (STM/S). Atomically flat facets witha root mean square roughness of 0.12 nm and the InGaAs (001) 4 × 2 surface reconstruction areobserved on the top facet of the NWs and the contacts. STS shows a surface bandgap variation of 30 meV from the middle to the end of the NWs, which is attributed to a compositional variation of the In/Ga element concentration. The well-defined facets and small bandgap variations found after area selective growth and atomic hydrogen cleaning are a good starting point for achieving high-quality interfaces during further processing.
|
|
| 10. |
- Meisner, Patrick, et al.
(författare)
-
Low-lying zeros in families of elliptic curve L-functions over function fields
- 2022
-
Ingår i: Finite Fields and their Applications. - : Elsevier BV. - 1071-5797 .- 1090-2465. ; 84
-
Tidskriftsartikel (refereegranskat)abstract
- We investigate the low-lying zeros in families of L-functions attached to quadratic and cubic twists of elliptic curves defined over Fq(T). In particular, we present precise expressions for the expected values of traces of high powers of the Frobenius class in these families with a focus on the lower order behavior. As an application we obtain results on one-level densities and we verify that these elliptic curve families have orthogonal symmetry type. In the quadratic twist families our results refine previous work of Comeau-Lapointe. Moreover, in this case we find a lower order term in the one-level density reminiscent of the deviation term found by Rudnick in the hyperelliptic ensemble. On the other hand, our investigation is the first to treat these questions in families of cubic twists of elliptic curves and in this case it turns out to be more complicated to isolate lower order terms due to a larger degree of cancellation among lower order contributions.
|
|
